Trial Profile
Potent Alloimmune Modulation By Efalizumab in Islet Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2015
Price :
$35
*
At a glance
- Drugs Efalizumab (Primary) ; Belatacept
- Indications Islet cell transplant rejection
- Focus Pharmacodynamics
- 22 Dec 2015 New trial record